Centauri Therapeutics has raised over $32.6 million in Series A financing to support the development of novel antibacterial candidates for difficult-to-treat infections, the company announced Wednesday. Investors in the round include Boehringer Ingelheim Venture Fund, Evotec and Novo Holdings REPAIR Impact Fund.
The London-based biotech won CARB-X backing in 2020 for its ABX01 dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens (including drug-…